Karolina Winsko-SzczęSnowicz
Research Subjects
Karolina Winsko-SzczęSnowicz has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Mirosława Püsküllüoğlu
Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland
3 shared publications Aleksandra Konieczna
Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology-National Research Institute, Warsaw, Poland
2 shared publicationsAleksandra Łacko
Department of Oncology, Breast Unit Clinical Oncology Day Care Department, Wroclaw Medical University, Lower Silesian Comprehensive Cancer Center, Wrocław, Poland
2 shared publicationsAnika PęKala
Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Łódź, Poland
2 shared publicationsBogumiła Czartoryska-Arłukowicz
Department of Clinical Oncology, M. Sklodowska-Curie Bialystok Oncology Center, Białystok, Poland
2 shared publicationsIveta KolářOvá
Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
2 shared publications
Latest Publications
- 2 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2665-2674
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort
Background Programmed death ligand 1 (PD-L1) expression, assessed by the combined positive score (CPS), is an established predictive biomarker for first-line chemo-immunotherapy in metastatic triple-negative breast cancer (mTNBC). In routine practice, CPS testing is heterogeneous and its relationship with outcomes in later-line, sacituzumab govitecan (SG)-treated patients with mTNBC is not well described. We aimed to assess clinicopathological correlates of CPS and its association with survival in this cohort. Methods We conducted a retrospective, multicenter study within the Central European Breast Cancer Collaboration (CEBCC)-102 project. CPS was locally assessed by validated immunohistochemistry. Survival outcomes: overall survival (OS), post-metastatic survival (PMS), and metastasis-free interval, were assessed with the Kaplan–Meier method. Results Of 303 women from the Czech Republic, Poland, and Slovakia with mTNBC treated with SG in ≥ 2 line, 107 (35.3%) with available CPS results were included in this analysis. CPS was positive (≥ 10) in 51/107 patients (47.7%) without significant demographic or disease-specific differences. During a median follow-up of 40 months, CPS-positive status may suggest worse outcomes in this cohort in multivariate analysis despite partial first-line chemo-immunotherapy exposure: OS 41.6 versus 67.7 months (HR 2.2, 95% CI: 1.1–4.5, p = 0.027) and PMS 20.2 versus 27.1 months (HR = 2.3, 95% CI: 1.2–4.2, p = 0.009). Conclusions In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating. Graphical abstract
- 2 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2665-2674
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort
Background Programmed death ligand 1 (PD-L1) expression, assessed by the combined positive score (CPS), is an established predictive biomarker for first-line chemo-immunotherapy in metastatic triple-negative breast cancer (mTNBC). In routine practice, CPS testing is heterogeneous and its relationship with outcomes in later-line, sacituzumab govitecan (SG)-treated patients with mTNBC is not well described. We aimed to assess clinicopathological correlates of CPS and its association with survival in this cohort. Methods We conducted a retrospective, multicenter study within the Central European Breast Cancer Collaboration (CEBCC)-102 project. CPS was locally assessed by validated immunohistochemistry. Survival outcomes: overall survival (OS), post-metastatic survival (PMS), and metastasis-free interval, were assessed with the Kaplan–Meier method. Results Of 303 women from the Czech Republic, Poland, and Slovakia with mTNBC treated with SG in ≥ 2 line, 107 (35.3%) with available CPS results were included in this analysis. CPS was positive (≥ 10) in 51/107 patients (47.7%) without significant demographic or disease-specific differences. During a median follow-up of 40 months, CPS-positive status may suggest worse outcomes in this cohort in multivariate analysis despite partial first-line chemo-immunotherapy exposure: OS 41.6 versus 67.7 months (HR 2.2, 95% CI: 1.1–4.5, p = 0.027) and PMS 20.2 versus 27.1 months (HR = 2.3, 95% CI: 1.2–4.2, p = 0.009). Conclusions In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating. Graphical abstract
- Open Access
- 12 January 2026
- Published by Elsevier in The Breast
- Vol. 85, 104699
Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
- 12 January 2026
- Published by Elsevier in The Breast
- Vol. 85, 104699
Open AccessTiming of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- p. 1-10
Germline BRCA1/2 Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis
Background: Germline BRCA1/2 mutations may influence sensitivity to systemic therapy in triple-negative breast cancer (TNBC), but their association with outcomes of first-line pembrolizumab plus chemotherapy remains uncertain. This study aimed to assess the association between germline BRCA1/2 mutation status and treatment outcomes in patients with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10 advanced TNBC receiving first-line pembrolizumab plus chemotherapy. Methods: This planned biomarker subanalysis of the retrospective, 20-centre CEBCC-101 cohort included 139 patients with documented germline BRCA1/2 status (gBRCA1/2m, n = 23; gBRCA1/2wt, n = 116). Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated using univariable and multivariable analyses. Results: Patients with gBRCA1/2m were younger than those with gBRCA1/2wt (median 51.5 vs. 56.3 years; p = 0.038), with no other significant differences in assessed baseline characteristics. ORR was 78.3% versus 52.2%, respectively (p = 0.038; adjusted OR 6.172, 95% CI 1.581–24.091; p = 0.009). Median PFS was 11.1 versus 8.3 months (log-rank p = 0.181; adjusted HR 0.602, 95% CI 0.331–1.096; p = 0.097) and median OS was 26.1 versus 20.4 months (log-rank p = 0.244; adjusted HR 0.427, 95% CI 0.183–0.996; p = 0.049). No statistically significant differences in the analysed grade ≥ 2 adverse-event categories were detected. Conclusions: In this planned CEBCC-101 subanalysis, documented germline BRCA1/2 status was associated with a higher ORR during first-line pembrolizumab plus chemotherapy. Without a chemotherapy-only comparator, this association cannot be attributed specifically to pembrolizumab and may partly reflect greater sensitivity to DNA-damaging chemotherapy. No statistically significant safety differences were detected. Survival findings remain exploratory.
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- p. 1-10
Germline BRCA1/2 Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis
Background: Germline BRCA1/2 mutations may influence sensitivity to systemic therapy in triple-negative breast cancer (TNBC), but their association with outcomes of first-line pembrolizumab plus chemotherapy remains uncertain. This study aimed to assess the association between germline BRCA1/2 mutation status and treatment outcomes in patients with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10 advanced TNBC receiving first-line pembrolizumab plus chemotherapy. Methods: This planned biomarker subanalysis of the retrospective, 20-centre CEBCC-101 cohort included 139 patients with documented germline BRCA1/2 status (gBRCA1/2m, n = 23; gBRCA1/2wt, n = 116). Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated using univariable and multivariable analyses. Results: Patients with gBRCA1/2m were younger than those with gBRCA1/2wt (median 51.5 vs. 56.3 years; p = 0.038), with no other significant differences in assessed baseline characteristics. ORR was 78.3% versus 52.2%, respectively (p = 0.038; adjusted OR 6.172, 95% CI 1.581–24.091; p = 0.009). Median PFS was 11.1 versus 8.3 months (log-rank p = 0.181; adjusted HR 0.602, 95% CI 0.331–1.096; p = 0.097) and median OS was 26.1 versus 20.4 months (log-rank p = 0.244; adjusted HR 0.427, 95% CI 0.183–0.996; p = 0.049). No statistically significant differences in the analysed grade ≥ 2 adverse-event categories were detected. Conclusions: In this planned CEBCC-101 subanalysis, documented germline BRCA1/2 status was associated with a higher ORR during first-line pembrolizumab plus chemotherapy. Without a chemotherapy-only comparator, this association cannot be attributed specifically to pembrolizumab and may partly reflect greater sensitivity to DNA-damaging chemotherapy. No statistically significant safety differences were detected. Survival findings remain exploratory.